Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
TP-38
Teva Pharma GmbH
Glioblastoma Multiforme
1 trial -
TV-1380 150 mg
Teva Pharma GmbH
Cocaine Addiction
1 trial -
TV-45070
Teva Pharma GmbH
Osteoarthritis of the Knee
1 trial -
TV-45070
Teva Pharma GmbH
Postherpetic Neuralgia
1 trial -
Talampanel
Teva Pharma GmbH
Epilepsy
1 trial -
Talampanel
Teva Pharma GmbH
ALS
1 trial -
Talampanel
Teva Pharma GmbH
Amyotrophic Lateral Sclerosis
1 trial -
Talampanel
Teva Pharma GmbH
Glioblastoma Multiforme
2 trials -
Tiotropium HFA BAI 4.5 mcg
Teva Pharma GmbH
COPD
1 trial -
Tiotropium HFA BAI 5 mcg
Teva Pharma GmbH
Chronic Obstructive Pulmonary Disease
1 trial -
Tizanidine (sublingual or oral)
Teva Pharma GmbH
Muscle Spasticity
1 trial -
armodafinil
Teva Pharma GmbH
Schizophrenia
2 trials -
autologous mesenchymal stem cells implantation
Teva Pharma GmbH
Tibial Fracture
1 trial -
bendamustine
Teva Pharma GmbH
Hodgkin Lymphoma
2 trials -
bendamustine
Teva Pharma GmbH
Multiple Myeloma
1 trial -
bendamustine and rituximab
Teva Pharma GmbH
Non-Hodgkin's Lymphoma
1 trial -
cytarabine
Teva Pharma GmbH
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
1 trial -
desogestrel/ethinyl estradiol and ethinyl estradiol
Teva Pharma GmbH
Hemostasis
1 trial -
edratide
Teva Pharma GmbH
Systemic Lupus Erythematosus
1 trial -
etiprednol dicloacetate
Teva Pharma GmbH
Crohn's Disease
1 trial -
fremanezumab
Teva Pharma GmbH
Interstitial Cystitis
1 trial -
glatiramer acetate
Teva Pharma GmbH
Crohns Disease
1 trial -
glatiramer acetate 20 mg
Teva Pharma GmbH
Relapse-Remitting Multiple Sclerosis
1 trial -
glatiramer acetate 20 mg
Teva Pharma GmbH
Relapsing Remitting Multiple Sclerosis
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources